Zobrazeno 1 - 10
of 129
pro vyhledávání: '"John E, Tavis"'
Autor:
Dimitrios Moianos, Maria Makri, Georgia-Myrto Prifti, Aristeidis Chiotellis, Alexandros Pappas, Molly E. Woodson, Razia Tajwar, John E. Tavis, Grigoris Zoidis
Publikováno v:
Molecules, Vol 29, Iss 12, p 2942 (2024)
Hepatitis B virus (HBV) remains a global health threat. Ribonuclease H (RNase H), part of the virus polymerase protein, cleaves the pgRNA template during viral genome replication. Inhibition of RNase H activity prevents (+) DNA strand synthesis and r
Externí odkaz:
https://doaj.org/article/92d2fc12da214c62bb8eb197a88cae60
Autor:
Tobias Boettler, Upkar S. Gill, Lena Allweiss, Teresa Pollicino, John E. Tavis, Fabien Zoulim
Publikováno v:
JHEP Reports, Vol 4, Iss 6, Pp 100480- (2022)
Summary: Cure from chronic HBV infection is rare with current therapies. Basic research has helped to fundamentally improve our knowledge of the viral life cycle and virus-host interactions, and provided the basis for several novel drug classes that
Externí odkaz:
https://doaj.org/article/c73505d934a64b0292ee760cf659529d
Autor:
Jeffrey Lin, Maryam Zangi, Tanguturi Venkata Narayana Hajay Kumar, Makala Shakar Reddy, Lingala Vijaya Raghava Reddy, Subir Kumar Sadhukhan, Daniel P. Bradley, Brenda Moreira-Walsh, Tiffany C. Edwards, Austin T. O’Dea, John E. Tavis, Marvin J. Meyers, Maureen J. Donlin
Publikováno v:
ACS Omega, Vol 6, Iss 12, Pp 8477-8487 (2021)
Externí odkaz:
https://doaj.org/article/c5271212d8eb4b289be69aa7fe4eb678
Autor:
Alexander I. Mosa, Mounir G. AbouHaidar, Richard A. Urbanowicz, John E. Tavis, Jonathan K. Ball, Jordan J. Feld
Publikováno v:
Virology Journal, Vol 17, Iss 1, Pp 1-5 (2020)
Abstract Despite available treatments, a prophylactic HCV vaccine is needed to achieve elimination targets. HCV vaccine development has faltered largely because the extreme diversity of the virus limits the protective breadth of vaccine elicited anti
Externí odkaz:
https://doaj.org/article/acb15cf44180492da52495a5f8c2ccad
Autor:
Elizabeth Geerling, Valerie Murphy, Maria C Mai, E Taylor Stone, Andreu Gazquez Casals, Mariah Hassert, Austin T O'Dea, Feng Cao, Maureen J Donlin, Mohamed Elagawany, Bahaa Elgendy, Vasiliki Pardali, Erofili Giannakopoulou, Grigoris Zoidis, Daniel V Schiavone, Alex J Berkowitz, Nana B Agyemang, Ryan P Murelli, John E Tavis, Amelia K Pinto, James D Brien
Publikováno v:
PLoS ONE, Vol 17, Iss 9, p e0274266 (2022)
Rift Valley fever virus (RVFV) is a veterinary and human pathogen and is an agent of bioterrorism concern. Currently, RVFV treatment is limited to supportive care, so new drugs to control RVFV infection are urgently needed. RVFV is a member of the or
Externí odkaz:
https://doaj.org/article/f63b08d6f3224485b760c43c8a67f8c2
Autor:
Siyuan Hao, Kang Ning, Xiaomei Wang, Jianke Wang, Fang Cheng, Safder S. Ganaie, John E. Tavis, Jianming Qiu
Publikováno v:
Frontiers in Microbiology, Vol 11 (2020)
Bourbon virus (BRBV) was first isolated from a patient hospitalized at the University of Kansas Hospital in 2014. Since then, several deaths have been reported to be caused by BRBV infection in the Midwest and Southern United States. BRBV is a tick-b
Externí odkaz:
https://doaj.org/article/f17228f9b1bd48cfae19b7992e10b726
Autor:
Tshegofatso Ngwaga, Ling Kong, Derrick Lin, Cassandra Schoborg, Lynn E Taylor, Kenneth H Mayer, Robert S Klein, David D Celentano, Jack D Sobel, Denise J Jamieson, Caroline C King, John E Tavis, Jason T Blackard
Publikováno v:
PLoS ONE, Vol 15, Iss 8, p e0237162 (2020)
Viral diversity is an important feature of hepatitis C virus (HCV) infection and an important predictor of disease progression and treatment response. HIV/HCV co-infection is associated with enhanced HCV replication, increased fibrosis, and the devel
Externí odkaz:
https://doaj.org/article/d354eca1aa0e4625b818161e01601253
Autor:
Feng Cao, Cari Orth, Maureen J. Donlin, Patrick Adegboyega, Marvin J. Meyers, Ryan P. Murelli, Mohamed Elagawany, Bahaa Elgendy, John E. Tavis
Publikováno v:
ACS Omega, Vol 3, Iss 11, Pp 15125-15133 (2018)
Externí odkaz:
https://doaj.org/article/b20f095983cd4858a4b124a357ad0eac
Autor:
Georgia-Myrto Prifti, Dimitrios Moianos, Erofili Giannakopoulou, Vasiliki Pardali, John E. Tavis, Grigoris Zoidis
Publikováno v:
Pharmaceuticals, Vol 14, Iss 5, p 417 (2021)
Hepatitis B virus infection affects over 250 million chronic carriers, causing more than 800,000 deaths annually, although a safe and effective vaccine is available. Currently used antiviral agents, pegylated interferon and nucleos(t)ide analogues, h
Externí odkaz:
https://doaj.org/article/82478afa5f3746a0a81484546b91e960
Publikováno v:
Protein Science. 31
Hepatitis B virus (HBV) replicates by protein-primed reverse transcription. It chronically infects >250 million people, and the dominant anti-HBV drugs are nucleos(t)ide analogs targeting the viral polymerase (P). P has four domains, the terminal pro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d3954dae49e83db973b7174216e97b8
https://doi.org/10.1002/pro.4421
https://doi.org/10.1002/pro.4421